

---

## Acarix Q3 2023 - Soft sales but solid cost control

Redeye makes minor changes to its estimates following Acarix's Q3 2023 report, which featured lower sales and costs than we had anticipated. The company focuses on sales, and growth should take off in 2024 as contribution from the VA and IDN's materialize.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Acarix Q3 2023 - Soft sales but solid cost control](#)